Therapeutic effects of adipose-derived mesenchymal stem/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis
Open Access
- 7 October 2022
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 24 (1) , 1-13
Abstract
Background: Adipose-derived mesenchymal stem cells (ASCs) have gained attention as a new treatment for systemic sclerosis (SSc). Low-molecular-weight heparin (LMWH) enhances cell function and stimulates the production of hepatocyte growth factor (HGF) in a variety of cells. This study investigated the effects of LMWH on the functions of mouse ASCs (mASCs), and the therapeutic effects of mASCs activated with LMWH (hep-mASCs) in mouse models of SSc. Methods: The cellular functions of mASCs cultured with different concentrations of LMWH were determined. Mice were divided into four groups: bleomycin (BLM)-induced SSc (BLM-alone), BLM-induced SSc administered with mASCs (BLM-mASC), and BLM-induced SSc administered with mASCs activated with 10 or 100 μg/mL LMWH (BLM-hep-mASC); there were 9 mice per group (n = 9). Skin inflammation and fibrosis were evaluated using histological and biochemical examinations and gene expression levels. Results: In vitro assays showed that migration ability and HGF production were significantly higher in hep-mASCs than in mASCs alone. The mRNA expression levels of cell migration factors were significantly upregulated in hep-mASCs compared to those in mASCs alone. The hep-mASCs accumulated in the skin tissues more than mASCs alone. The thickness of skin and hydroxyproline content in BLM-hep-mASC groups were significantly decreased, and the skin mRNA expression levels of interleukin-2, α-smooth muscle actin, transforming growth factor β1, collagen type 1 alpha 1, and tissue inhibitor of metalloproteinase 2 were significantly downregulated compared to those in the BLM-alone group. Conclusions: hep-mASCs showed higher anti-inflammatory and anti-fibrotic effects than mASCs alone and may be a promising candidate for SSc treatment.Keywords
This publication has 50 references indexed in Scilit:
- Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicineExperimental & Molecular Medicine, 2013
- Familial Occurrence of Pulmonary Embolism after Intravenous, Adipose Tissue-Derived Stem Cell TherapyYonsei Medical Journal, 2013
- Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical TrialsPLOS ONE, 2012
- Hepatocyte Growth Factor Modulates Interleukin-6 Production in Bone Marrow Derived Macrophages: Implications for Inflammatory Mediated DiseasesPLOS ONE, 2010
- Synergism between Wnt3a and Heparin Enhances Osteogenesis via a Phosphoinositide 3-Kinase/Akt/RUNX2 PathwayJournal of Biological Chemistry, 2010
- Heparin promotes the growth of human embryonic stem cells in a defined serum-free mediumProceedings of the National Academy of Sciences, 2008
- Heparin and low-molecular-weight heparinThrombosis and Haemostasis, 2008
- Cyclophosphamide for scleroderma interstitial lung diseaseExpert Opinion on Investigational Drugs, 2007
- Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal CellsCirculation, 2004
- Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of sclerodermaGene Therapy, 2004